Alembic Limited

ALEMBICLTD.BO·BSE·Real Estate
Compare
97.60+3.02 (+3.19%)today
As of Nov 5, 2:14 PM IST · May be delayed up to 15 min · INR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close94.58
Open96.48
Day range96.4799.40
52-week range85.55125.70
Off day high−1.81%
Off 52-week high−22.35%
Volume35.11K
Avg. volume (3M)16.01K
Market cap25.06B
EPS (TTM)12.61
Forward P/E—
P/E ratio (TTM)7.74
Dividend yield2.49% (2.40)
Beta (5Y)0.37
Shares outstanding256.78M
Short interest—
Earnings dateAug 11, 2025 (est.)
Analyst target—
Profit margin144.76%

Against its peers

Compare in full ›
ALEMBICLTD.BO APLLTD.NS IOLCP.NS INDOCO.BO THEMISMED.NS AAREYDRUGS.NS
Market cap 25.06B 175.63B 55.50B 19.77B 9.44B 3.49B
P/E (TTM) 7.7 20.8 27.3 — 23.5 74.4
Forward P/E — 18.2 17.5 34.9 — —
Price/book 1.0 3.0 2.9 1.7 2.4 2.1
Dividend yield 2.49% 1.32% 0.54% 0.09% 0.50% —
1-year change −17.33% −0.94% +102.86% −19.23% −15.87% +10.12%
Today +3.19% −1.46% +2.89% +0.14% +2.13% +0.08%

The closest companies by business and industry (Real Estate - Development). Prices may be delayed up to 15 min.

EquityBulls··2 outletsPositive

Alembic Pharmaceuticals Ltd receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%.

Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP,…

More from 1 other outlet
News18·Positive

Alembic Pharma gets USFDA nod for generic ear infection drug

New Delhi, Oct 19 (PTI) Alembic Pharmaceuticals Ltd on Monday said it has received the final approval from the US Food and Drug Administration (USFDA) for its generic Ciprofloxacin and Dexamethasone Otic Suspension USP. The product is…

AZN

From the 4Search news index, newest first.

In the news

5mentions in 30 days
5with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance